Differentiation-inducing factor-1 reduces lipopolysaccharide-induced vascular cell adhesion molecule-1 by suppressing

Masaki Arioka1, Fumi Seto-Tetsuo2, Takeru Inoue3

  • 1Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.

Life Sciences
|November 19, 2023
PubMed
Abstract

Insights

Differentiation-inducing factor-1 (DIF-1) combats cancer metastasis by preventing tumor cells from adhering to blood vessels. It achieves this by inhibiting mTORC1-S6K signaling, reducing VCAM-1 expression on endothelial cells.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Differentiation-inducing factor-1 (DIF-1) from Dictyostelium discoideum shows anti-cancer properties.
  • DIF-1 inhibits cancer cell proliferation, motility, and metastasis in preclinical models.
  • The precise anti-metastatic mechanism of DIF-1, particularly its effect on tumor cell adhesion, requires elucidation.

Purpose of the Study:

  • To investigate the mechanism by which DIF-1 inhibits cancer metastasis.
  • To examine the effect of DIF-1 on circulating tumor cell adhesion to blood vessels.
  • To elucidate the molecular pathways involved in DIF-1's anti-metastatic activity.

Main Methods:

  • In vivo studies using C57BL/6 mice injected with melanoma cells and treated with DIF-1 and/or LPS.
  • In vitro cell adhesion assays using cancer cells and human umbilical vein endothelial cells.
  • Molecular analyses including western blotting, immunofluorescence staining, and flow cytometry.

Main Results:

  • DIF-1 administration suppressed lung colony formation in mice.
  • DIF-1 significantly inhibited cancer cell adhesion to endothelial cells.
  • DIF-1 reduced vascular cell adhesion molecule-1 (VCAM-1) expression in endothelial cells by inhibiting mTORC1-p70 S6 kinase signaling, without affecting cancer cell adhesion protein levels.

Conclusions:

  • DIF-1 effectively reduces tumor cell adhesion to blood vessels.
  • The anti-metastatic effect of DIF-1 is mediated by the inhibition of mTORC1-S6K signaling and subsequent downregulation of VCAM-1 on vascular endothelial cells.
  • DIF-1 holds promise as a potential therapeutic agent for developing anti-cancer drugs targeting metastasis.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K